Tema Oncology ETF Rating $25.16 +0.70 (+2.86%) As of 01/21/2025 03:49 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrends Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.79Holdings in CANC have an aggregate rating of Moderate Buy based on 600 analyst ratings issued in the past year covering 42 companies (81.0% of the portfolio).CANC Aggregate Price Target$25.16High Prediction$25.16Average Prediction$25.16Low Prediction$25.16Holdings in CANC have an aggregate price target of $25.16 and a range of $25.16 to $25.16 covering 42 companies (81.0% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy15 Buy rating(s)Moderate Buy23 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 42 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.57%GILDGilead Sciences$92.96+1.2%4.564 of 5 stars2.70$97.96 5.4%27Analyst RevisionPositive News5.01%REGNRegeneron Pharmaceuticals$687.80+0.9%4.6152 of 5 stars2.65$1,015.38 47.6%23News Coverage4.87%ARGXargenx$647.39+1.1%2.3509 of 5 stars2.86$658.39 1.7%22Gap Up4.48%INCYIncyte$73.47+2.1%4.7826 of 5 stars2.35$76.29 3.8%204.25%RVMDRevolution Medicines$40.16-0.3%4.4712 of 5 stars3.08$66.25 65.0%124.18%BPMCBlueprint Medicines$111.96+1.7%1.1236 of 5 stars2.65$122.72 9.6%20Short Interest ↑4.06%ILMNIllumina$141.31+3.4%4.5149 of 5 stars2.70$165.63 17.2%203.50%EXELExelixis$36.43+0.6%4.6945 of 5 stars2.53$35.50 -2.6%192.63%GMABGenmab A/S$21.80+4.8%4.3855 of 5 stars2.67$45.20 107.3%9Gap Up2.61%MREOMereo BioPharma Group$2.99+4.5%2.0533 of 5 stars3.43$7.83 162.0%7Positive NewsGap Down2.41%MRKMerck & Co., Inc.$96.18-1.8%4.9993 of 5 stars2.67$123.00 27.9%21Analyst ForecastNews CoveragePositive News2.38%SWTXSpringWorks Therapeutics$36.35+5.0%1.5088 of 5 stars3.00$70.00 92.6%62.36%GHGuardant Health$45.13+23.1%3.4378 of 5 stars3.00$40.60 -10.0%15Short Interest ↓News CoverageGap UpHigh Trading Volume1.98%BBIOBridgeBio Pharma$36.08+6.8%4.0981 of 5 stars2.86$48.08 33.3%14Short Interest ↑1.94%NUVLNuvalent$78.28+3.2%1.9823 of 5 stars2.86$112.36 43.5%141.89%DAWNDay One Biopharmaceuticals$12.24-2.4%1.7881 of 5 stars3.00$35.86 193.0%91.81%AGIOAgios Pharmaceuticals$33.23+2.5%3.8351 of 5 stars2.50$56.33 69.5%8Short Interest ↑1.80%EXASExact Sciences$54.26+4.9%4.819 of 5 stars2.94$72.94 34.4%181.59%CLDXCelldex Therapeutics$24.61+3.5%2.0616 of 5 stars2.88$62.25 152.9%8Short Interest ↑Positive News1.52%LNTHLantheus$94.05+2.8%4.5566 of 5 stars3.00$131.86 40.2%71.48%AMGNAmgen$274.81+1.0%4.891 of 5 stars2.44$314.91 14.6%27News CoveragePositive News1.43%SDGRSchrödinger$21.33+12.3%1.6743 of 5 stars2.82$32.90 54.2%11News Coverage1.37%NTLAIntellia Therapeutics$9.94+4.6%4.6594 of 5 stars2.72$51.06 413.7%181.36%CRSPCRISPR Therapeutics$41.51+2.4%2.5178 of 5 stars2.47$78.38 88.8%19Short Interest ↑Gap Up1.30%MRUSMerus$39.74+0.7%3.0765 of 5 stars3.14$85.64 115.5%141.22%ACLXArcellx$66.57+0.1%3.2663 of 5 stars3.13$105.93 59.1%15Short Interest ↑1.09%BNTXBioNTech$117.25+4.8%1.7927 of 5 stars2.88$142.72 21.7%171.01%SMMTSummit Therapeutics$22.10+16.1%2.914 of 5 stars2.86$33.57 51.9%7Analyst ForecastNews Coverage0.91%NRIXNurix Therapeutics$19.60+2.4%2.1902 of 5 stars2.94$30.35 54.9%17Analyst Forecast0.88%IDYAIDEAYA Biosciences$23.15+4.4%4.0937 of 5 stars2.94$53.67 131.8%16Short Interest ↑0.86%COGTCogent Biosciences$8.20+2.1%1.5543 of 5 stars2.57$14.33 74.8%7Short Interest ↑0.84%MRNAModerna$35.89+5.4%4.7869 of 5 stars2.13$75.58 110.6%23Gap Up0.79%LEGNLegend Biotech$34.67+6.2%2.7536 of 5 stars3.00$80.62 132.5%13Analyst ForecastShort Interest ↓0.78%ORICORIC Pharmaceuticals$10.00+4.4%3.7502 of 5 stars3.00$18.29 82.9%8Gap Up0.74%CGEMCullinan Therapeutics$10.42+1.6%2.0077 of 5 stars3.00$31.67 203.9%70.71%RCUSArcus Biosciences$14.11+0.6%2.0617 of 5 stars3.00$34.00 141.0%9News Coverage0.70%IMCRImmunocore$30.00+3.4%2.5876 of 5 stars2.54$65.64 118.8%13Positive News0.60%JANXJanux Therapeutics$40.91+0.5%3.5227 of 5 stars3.08$89.90 119.8%130.57%RLAYRelay Therapeutics$4.66+4.5%2.4429 of 5 stars2.91$20.50 339.9%110.57%JSPRJasper Therapeutics$5.70+3.4%2.7345 of 5 stars3.00$67.75 1,088.6%10Short Interest ↑0.51%CGONCG Oncology$30.00+3.2%1.3231 of 5 stars3.10$63.88 112.9%100.40%ARVNArvinas$18.57+2.9%2.6157 of 5 stars2.93$63.50 241.9%15 This page (NASDAQ:CANC) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts